{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:16:29Z","timestamp":1793412989737,"version":"4.5.0"},"reference-count":36,"publisher":"BMJ","issue":"9","funder":[{"name":"J. Arch McNamara Retina Research Fund","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2024,1,19]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>To assess the anatomical and functional outcomes in eyes with persistent diabetic macular oedema (pDME) on chronic anti-vascular endothelial growth factor therapy switched to intravitreal faricimab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with pDME on chronic anti-vascular endothelial growth factor therapy that were switched to faricimab and received at least three injections at our institution between April 2022 and May 2023 were included in this study. Patients were excluded if they had complete response to previous treatment but were switched to extend treatment intervals if they had steroid or laser treatment for DME within 6 months prior to switch. Clinical and imaging data were extracted from the electronic medical record. Central foveal thickness (CFT) and Snellen visual acuity (VA) were obtained before and after three intravitreal faricimab injections. Generalised estimating equations were used to analyse the change in CFT and VA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>During the study period, 69 eyes of 53 patients met inclusion criteria. The mean age was 68.6\u00b19.0 years. The mean number of injections prior to switch was 18.1\u00b116.0. Pre-switch mean logarithm of the minimal angle of resolution VA was 0.40\u00b10.30 (Snellen equivalent 20\/50) and 0.38\u00b10.27 (Snellen equivalent 20\/48) after three faricimab injections (p=0.397). Mean CFT improved from 380\u00b1155 microns to 323\u00b1147 microns (p&lt;0.001). No ophthalmic or systemic adverse events occurred during the study period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Intravitreal faricimab can improve anatomic outcomes while maintaining visual acuity in eyes with pDME previously treated with anti-VEGF therapy.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjo-2023-324394","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T18:20:11Z","timestamp":1707762011000},"page":"1257-1262","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema"],"prefix":"10.1136","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1013-5537","authenticated-orcid":false,"given":"Asad Farooq","family":"Durrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5435-7369","authenticated-orcid":false,"given":"Bita","family":"Momenaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudheshna","family":"Vemula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saagar A","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2761-4219","authenticated-orcid":false,"given":"Jason","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen C","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J","family":"Spirn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Klufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9115-6080","authenticated-orcid":false,"given":"Sunir J","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F","family":"Vander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D","family":"Regillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay E","family":"Kuriyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yonekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"2024082203451040000_108.9.1257.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.027"},{"key":"2024082203451040000_108.9.1257.2","unstructured":"Photocoagulation for diabetic macular edema . Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol Chic Ill 1960:1796\u2013806."},{"key":"2024082203451040000_108.9.1257.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.039"},{"key":"2024082203451040000_108.9.1257.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.006"},{"key":"2024082203451040000_108.9.1257.5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ajo.2018.07.030","article-title":"Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T","volume":"195","author":"Bressler","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"2024082203451040000_108.9.1257.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.09.076"},{"key":"2024082203451040000_108.9.1257.7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","article-title":"Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial","volume":"136","author":"Maturi","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"2024082203451040000_108.9.1257.8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.survophthal.2022.11.008","article-title":"Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods","volume":"68","author":"Sorour","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"2024082203451040000_108.9.1257.9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/13543784.2021.1879791","article-title":"Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases","volume":"30","author":"Nicol\u00f2","year":"2021","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"2024082203451040000_108.9.1257.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070459","article-title":"Angiopoietin-2 is critical for cytokine-induced vascular leakage","volume":"8","author":"Benest","year":"2013","journal-title":"PLoS One"},{"key":"2024082203451040000_108.9.1257.11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajo.2016.04.017","article-title":"Pro-permeability Factors in Diabetic Macular Edema; the Diabetic Macular Edema Treated With Ozurdex Trial","volume":"168","author":"Campochiaro","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"2024082203451040000_108.9.1257.12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"The Lancet"},{"key":"2024082203451040000_108.9.1257.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.02.023"},{"key":"2024082203451040000_108.9.1257.14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcjo.2021.05.018","article-title":"Agreement of optical coherence tomography thickness measurements between Heidelberg Eye Explorer and ImageJ software","volume":"57","author":"Mahmoudzadeh","year":"2022","journal-title":"Canadian Journal of Ophthalmology"},{"key":"2024082203451040000_108.9.1257.15","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","article-title":"Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic","volume":"37","author":"Stanga","year":"2023","journal-title":"Eye (Lond)"},{"key":"2024082203451040000_108.9.1257.16","unstructured":"Aziz AA , Khan H , Abbey AM , et al . The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study. Invest Ophthalmol Vis Sci 2023;64."},{"key":"2024082203451040000_108.9.1257.17","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye (Lond)"},{"key":"2024082203451040000_108.9.1257.18","doi-asserted-by":"crossref","unstructured":"Rush RB , Rush SW . . OPTH 2022;Volume 16:2797\u2013801. 10.2147\/OPTH.S381503","DOI":"10.2147\/OPTH.S381503"},{"key":"2024082203451040000_108.9.1257.19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of A Randomized Clinical Trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"2024082203451040000_108.9.1257.20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.oret.2017.07.004","article-title":"A Prospective Randomized Comparative Dosing Trial of Ranibizumab in Bevacizumab-Resistant Diabetic Macular Edema","volume":"2","author":"Ehlers","year":"2018","journal-title":"Ophthalmology Retina"},{"key":"2024082203451040000_108.9.1257.21","doi-asserted-by":"crossref","unstructured":"Chen YY , Chang PY , Wang JK . Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept. Asia Pac J Ophthalmol (Phila) 2017;6. doi:10.22608\/APO.2016186","DOI":"10.22608\/APO.2016186"},{"key":"2024082203451040000_108.9.1257.22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ajo.2015.12.030","article-title":"Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema","volume":"164","author":"Rahimy","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"2024082203451040000_108.9.1257.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.024"},{"key":"2024082203451040000_108.9.1257.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-022-02761-9","article-title":"Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration","volume":"23","author":"Gyenes","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"2024082203451040000_108.9.1257.25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000360186","article-title":"Detection of antiranibizumab antibodies among patients with exudative age-related macular degeneration","volume":"232","author":"Leveziel","year":"2014","journal-title":"Ophthalmologica"},{"key":"2024082203451040000_108.9.1257.26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/OPTH.S19555","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin\u00ae) in rabbits","volume":"5","author":"Sinapis","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"2024082203451040000_108.9.1257.27","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41433-019-0670-1","article-title":"Faricimab: expanding horizon beyond VEGF","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye"},{"key":"2024082203451040000_108.9.1257.28","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6386"},{"key":"2024082203451040000_108.9.1257.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)61115-7"},{"key":"2024082203451040000_108.9.1257.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.06.052"},{"key":"2024082203451040000_108.9.1257.31","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181c2e0d6"},{"key":"2024082203451040000_108.9.1257.32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","article-title":"Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema","volume":"132","author":"Sun","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2024082203451040000_108.9.1257.33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.oret.2017.01.017","article-title":"Restoration of Photoreceptor Outer Segments up to 24 Months after Pars Plana Vitrectomy in Patients with Diabetic Macular Edema","volume":"1","author":"Miyamoto","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"2024082203451040000_108.9.1257.34","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3109\/02713683.2015.1113430","article-title":"Interdigitation Zone Band Restoration After Treatment of Diabetic Macular Edema","volume":"41","author":"Serizawa","year":"2016","journal-title":"Curr Eye Res"},{"key":"2024082203451040000_108.9.1257.35","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.oret.2019.06.010","article-title":"Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index","volume":"3","author":"Ehlers","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"2024082203451040000_108.9.1257.36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jamaophthalmol.2016.4820","article-title":"Evaluating Effects of Switching Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema","volume":"135","author":"Ferris","year":"2017","journal-title":"JAMA Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2023-324394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T10:56:23Z","timestamp":1724324183000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2023-324394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,8,22]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/bjo-2023-324394"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2023-324394","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]}}}